Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01575288 · ClinicalTrials.gov registry record · NA

Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults

A NA study, sponsored by University of Colorado, Boulder.

Completed
Registry status
NA
Development phase
110
Enrollment target

NCT01575288: Completed NA study, sponsored by University of Colorado, Boulder.

NCT01575288 is a NA study that has completed, run by University of Colorado, Boulder. The registered enrollment target is 110 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01575288, a NA study, has completed, sponsored by University of Colorado, Boulder.

COMPLETED
Registry status
NA
Development phase
110 participants
Enrollment target

Study Summary

The proposed study will assess the ability of a naturally occurring sugar to improve the function of arteries with age. Overall, the proposed research project has the long-term potential to influence clinical practice guidelines by establishing a novel, easy to deliver, cost-effective therapy for treating age-associated arterial dysfunction and reducing the risk of cardiovascular disease with age.

Primary Outcome

Arterial pulse wave velocity

Interventions

  • DRUG Placebo
  • DRUG High-dose trehalose

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2012-05
Est. Completion 2015-12
Phase NA
University of Colorado, Boulder

69 total trials

What the finished NCT01575288 record still lists

NCT01575288 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01575288 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01575288 about?

NCT01575288 is a clinical study titled "Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults". The proposed study will assess the ability of a naturally occurring sugar to improve the function of arteries with age. Overall, the proposed research project has the long-term potential to influence clinical practice guidelines by establishing a novel, easy to deliver, cost-effective therapy for tr...

What is the current status of trial NCT01575288?

This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2012-05. Estimated completion is 2015-12.

What interventions are being tested in trial NCT01575288?

The interventions under investigation include: Placebo (DRUG), High-dose trehalose (DRUG).

Who is sponsoring clinical trial NCT01575288?

This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01575288's enrollment target sits among peer trials

110 816th of 2000 higher than 1,176 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01575288, the US trial registry maintained by the National Library of Medicine. NCT01575288 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.